Rubicon Research
Differentiated formulations & specialty pharma for regulated markets. The default deep-dive: products, pipeline, regulatory, manufacturing, R&D, competitive benchmarking, an AI transformation roadmap and management meeting prep.
A deep-dive on Rubicon Research — the company this whole platform is built around. It's a US-focused 'complex generics' specialist: it engineers hard-to-copy versions of medicines (extended-release pills, nasal sprays, drug-device combos) and sells them in regulated markets.
Use the tab bar above to move between Overview, Financials, Products, Pipeline, Regulatory, Manufacturing, R&D, Competitors, AI Opportunities, the Strategy Memo and Meeting Prep. A teal badge means the data is reported/sourced; an amber 'Modeled estimates' badge flags fields that aren't publicly disclosed.
- ANDA
- — The US FDA application to sell a generic drug. Rubicon has 72 approved.
- NDA / 505(b)(2)
- — Filings for new or improved (reformulated) branded drugs — higher value than plain generics.
- NDDS
- — Novel Drug Delivery System — Rubicon's tech for controlled-release, taste-masking, etc.
- OFS
- — Offer For Sale — existing investors selling shares in the IPO (vs. fresh capital raised).
Company Snapshot
Business Description
Rubicon Research (founded 1999, promoted by General Atlantic) is among the few Indian pharma companies with a near-complete focus on the US / regulated markets. It develops complex/differentiated generics, specialty products and drug-device combinations using proprietary novel-drug-delivery platforms. It IPO'd on the NSE & BSE on 16-Oct-2025 (issue ₹485) and trades around ₹1,257 (Jun-2026), ~2.6× the issue price. FY25 revenue ₹1,284 Cr (3-yr revenue CAGR >80%), with 72 active ANDAs and 9 NDAs approved.
Rubicon is not a scale commodity generics player nor a branded-India compounder. It sits in the high-barrier complex-generics + formulation-technology pocket — competing on dosage-form difficulty, IP navigation and US regulatory execution, with an emerging specialty/505(b)(2) optionality.
Business Model Map
R&D-led, regulated-market value creation flow
Quality Score
Growth Score
Regulatory Risk
Listed on NSE/BSE 16-Oct-2025 at ₹485; trading ~₹1,257 (11-Jun-2026, mcap ₹21,088 Cr, ~104× trailing P/E) — ~2.6× the issue price, so trailing 1Y/3Y/5Y CAGRs are not yet meaningful. FY25 financials from the DRHP/post-IPO disclosures. Revenue-mix, EV/EBITDA & P/B are modeled (reported book value is thin post-OFS).